RU-NT-206 is a small molecule inhibitor targeting the P-stalk binding pocket of ricin toxin A subunit (RTA) with IC50 of 7 uM, inhibits catalytic activity and protects cells against ricin and Stx2 holotoxins.

RTI-263 (SerPheLysAsn-NH2) is a potent, selective tetrapeptide neuropeptide S receptor (NPSR, GPR154) biased agonist with EC50 of 3.02 nM for hNPSR calcium mobilization.

RPI-194 is a novel troponin activator that binds to cardiac/slow skeletal muscle troponin, binds to cardiac troponin with KD of 24 uM, stabilizing the activated complex between troponin C and the switch region of troponin I.

RPE65-61 ((±)-RPE65-61) is a selective, non-retinoid and uncompetitive inhibitor of RPE65 (a key enzyme in the visual cycle), inhibits the retinol isomerase activity of RPE65 in vitro with IC50 of 80 nM.

Ro 48-8071 is a potent 2,3-oxidosqualene cyclase (OSC) inhibitor with IC50 of 6.5 nM.

RG100204 is a novel selective, small molecule inhibitor of the neutral solute channel Aquaporin 9 (AQP9), inhibits AQP9 water permeability (IC50=110 nM) and AQP9 glycerol permeability (IC50=76 nM).

RF03176 is a selective AQP9 inhibitor with IC50 of 1.3 uM (inhibition of CHO-AQP9 cell water permeability).

RECTAS is a small molecule splice modulator that corrects aberrant splicing of familial dysautonomia (FD), promotes exon 20 inclusion of IKBKAP pre-mRNA and expression of IKAP.

RBS-10 is a small molecule that shows preferential cytotoxicity against cells pan-resistant to degraders, acts as a prodrug bioactivated by the oxidoreductase enzyme NQO1.

RA 5557 is a brain-penetrant, selective, oral UGT8 inhibitor, inhibits galactosylceramide biosynthesis.

R805 is a small molecule modulator of gp130 receptor pro-inflammatory signaling, targets a signaling tyrosine 814 (Y814) within gp130, modulates gp130 Y814 upstream of the SRC and MAPK circuit, elicits a protective effect on tissues after injury.

QP5038 is a potent inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with IC50 of 3.8 nM, shows promising in vitro and in vivo anti-tumor efficacies.

PXS-6302 (PXS6302) is a potent, irreversible pan-lysyl oxidase (pan-LOX) inhibitor with IC50 of 3.7 uM and 3.4/0.4/1.5/0.3 uM for bovine (aorta) LOX and rh LOXL1/2/3/4, respectively.

PXS-5505 dihydrochloride monohydrate is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (pan-LOX) family members, with potential antifibrotic activity.

PXS-5129A is the pro-drug form of PXS-5120A, a potent, selective, irreversible inhibitor of Lysyl oxidase-like 2 (LOXL2).

PTI-125 (Simufilam, Sumifilam) is a small molecule targeting scaffolding protein filamin A (FLNA), preferentially binds altered FLNA and restores its native conformation.

PT91 is a small-molecule GPR27 (SREB1) agonist with pEC50 of 6.15 (human GPR27) in β-arrestin 2 recruitment-based firefly luciferase complementation assay, Emax=100%.

PSB-KK-1415 is a selective GPR18 agonist with EC50 of 19.1 nM (hGPR18) in β-arrestin recruitment assays, shows no activity against GPR55.

PSB-CB-148 is a potent, selective antagonist of GPR18.

PSB-22040 is a potent, selective agonist of MAS-related Gq protein-coupled receptor X4 (MRGPRX4) with EC50 of 19.2 nM/30.0 nM in Ca2+ assay/β-arrestin assays (variant 83S), respectively.

PSB-22034 is a potent, selective agonist of MAS-related Gq protein-coupled receptor X4 (MRGPRX4) with EC50 of 11.2 nM/32.0 nM in Ca2+ assay/β-arrestin assays (variant 83S), respectively.

PRG-A01 is a chemical inhibitor against SOD1 misfolding and aggregation, inhibits the neuronal cell death caused by mutant-SOD1 overexpression.

PPA-904 is a specific phenothiazine photosensitizer in photodynamic therapy (PDT) research, especially topical application for cutaneous leishmaniasis in vivo.

Pixatimod (PG545) is a heparan sulfate (HS) mimetic and anticancer agent and a potent inhibitor of heparanase.

PF-07247685 (PF-07247685) is a potent, allosteric branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with in vitro IC50 of 0.86 nM, and SPR Kd of 0.68 nM.

PF-07208254 (PF 07208254) is a potent, allosteric branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with in vitro IC50 of 110 nM and Ki of 54 nM.

PEPCKi is a small molecule inhibitor of hosphoenolpyruvate carboxykinase (PEPCK), blocks lactate utilization and impairs tumor growth in colorectal cancer.

PDDC is the first potent, selective, orally-available, and brain-penetrable nSMase2 (neutral sphingomyelinase 2) inhibitor with pIC50 of 6.57.

PCiB-3 is a small molecule inhibitor capable of inhibiting phosphatidylcholine (PC) biogenesis with IC50 of 0.4 uM, inhibits the phosphatidylethanolamine (PE) methyltransferase activity of Cho2.

PCiB-2 is a small molecule inhibitor capable of inhibiting phosphatidylcholine (PC) biogenesis with IC50 of 2.0 uM, inhibits the phosphatidylethanolamine (PE) methyltransferase activity of Cho2, induces mitochondrial division.